Imugene Ltd (ASX:IMU) and Medical University Vienna have presented positive new data on the PD-1 mimotope cancer vaccine program at the American Association for Cancer Research (AACR) 2019 Annual Meeting.
The presentation by Dr Joshua Tobias from the Medical University Vienna was entitled ‘PD1 B cell mimotopes with functional PD1-PDL1 blocking capacity and anti-tumor activity: New strategy for a multi-level cancer immunotherapy.’
@TeamImugene and MedUni Vienna mimotope vaccines inhibit tumor growth in HER-2+ breast cancer models READ today's ASX news https://t.co/UDejcS62wj $IMU #CancerVaccine #BreastCancer #ImmunoOncology (ASX:IMU) pic.twitter.com/VRyJLdWtMY— Imugene | Cancer Immunotherapies (@TeamImugene) April 2, 2019
Imugene’s PD-1 B-cell vaccine, known as KEY-Vaxx, aims to induce the body to produce antibodies that block PD-1 signalling, and thus produce an anticancer effect.
The research led by Professor Ursula Wiedermann from the Medical University Vienna successfully inhibited tumor growth in a syngeneic mouse model of HER-2+ breast cancer via both passive and active immunisation strategies with PD-1 targeting B-cell cancer vaccines.
For the active immunisation study, which is of greatest interest and potential value to cancer researchers, the surrogate vaccine derived from mouse PD-1 was able to “brake tolerance” thereby inducing a sustained antibody response to the self-protein PD-1.
Importantly, the findings provide proof of concept and validation for Imugene’s human PD-1 cancer vaccine KEY-Vaxx.